S&P 500
(-0.16%) 5 464.62 points
Dow Jones
(0.04%) 39 150 points
Nasdaq
(-0.18%) 17 689 points
Oil
(-0.86%) $80.59
Gas
(-0.80%) $2.72
Gold
(-1.45%) $2 334.70
Silver
(-4.03%) $29.58
Platinum
(1.22%) $996.30
USD/EUR
(0.09%) $0.935
USD/NOK
(0.17%) $10.56
USD/GBP
(0.12%) $0.791
USD/RUB
(2.05%) $89.06

Realtime updates for Burning Rock Biotech Ltd [BNR]

Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
Last Updated21 Jun 2024 @ 16:00

-1.04% $ 6.68

Live Chart Being Loaded With Signals

Commentary (21 Jun 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.20% compare to its pairs and should correct upwards.
Profile picture for Burning Rock Biotech Ltd

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services...

Stats
Today's Volume 2 092
Average Volume 5 311
Market Cap 71.75M
EPS $-1.580 ( Q4 | 2024-04-29 )
Next earnings date ( $0 ) 2024-08-29
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -0.840
(Sector) 42.63
(Industry) 0
ATR14 $0 (0.00%)
ACRS 1.77%
AKU -17.87%
APDN 0.04%
BDSX 6.21%
BIOC 0.00%
BNGO -6.81%
BNR -1.04%
CDNA 0.64%
CEMI 0.22%
CHEK -3.83%
CNTG -9.79%
CSTL 1.52%
DMTK -3.14%
DRIO 11.01%
EXAS 1.93%
FLDM -7.02%
FLGT 1.10%
GENE 3.03%
GH 0.00%
GTH 0.12%
HTGM 0.00%
ICLR 0.88%
IDXX -0.05%
ILMN 0.30%
ISPC -5.86%
LAB 0.52%
LMDX 0.00%
MDXH -1.50%
ME 1.39%
MEDP 0.85%
MYGN 1.93%
MYNZ -19.82%
NDRA 3.04%
NEO 1.23%
NEOG 0.42%
NOTV 4.65%
NTRA -0.08%
OCDX 0.92%
OLK 0.31%
OPGN 2.12%
OPK -1.61%
PMD 2.62%
PRPO -3.30%
PSNL -0.81%
RDNT 2.55%
SERA -6.21%
SHC 3.71%
SQL 0.00%
STIM 2.23%
STRR -2.93%
STRRP 3.89%
SYNH 0.02%
TRIB -0.80%
TTOO 2.95%
TWST 4.58%
VIVO 0.00%
XGN 0.00%
Correlation (AI algo v.1.1b): Undervalued: 0.20% $6.69 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Burning Rock Biotech Ltd Correlation

10 Most Positive Correlations
OZEM1
BRSH0.951
PUBM0.947
EBAY0.946
ROOT0.944
ANIP0.944
RNA0.94
NTAP0.938
IINN0.937
NTRA0.936
10 Most Negative Correlations
XMTR-0.979
LPSN-0.954
TTEC-0.952
RETO-0.951
HRZN-0.948
SMSI-0.947
NARI-0.947
ASTR-0.946
TWKS-0.944
EEIQ-0.944

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Burning Rock Biotech Ltd Financials

Annual 2023
Revenue: $537.44M
Gross Profit: $363.23M (67.59 %)
EPS: $-6.38
FY 2023
Revenue: $537.44M
Gross Profit: $363.23M (67.59 %)
EPS: $-6.38
FY 2022
Revenue: $563.24M
Gross Profit: $380.04M (67.47 %)
EPS: $-9.35
FY 2021
Revenue: $507.86M
Gross Profit: $364.15M (71.70 %)
EPS: $-7.65

Financial Reports:

No articles found.

Burning Rock Biotech Ltd Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Burning Rock Biotech Ltd

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Total Execution Time: 1.0529658794403 seconds
Number of API calls: 3
Number of DB calls: 9